Most men who ask us about semaglutide do not need the obesity dose. They have read the headline trial results, seen the 2.4 mg figure, and assumed that is the protocol. It is one protocol. It is not the only one.
The GLP-1 microdose is a different conversation. Lower weekly dose, slower onset, narrower side-effect profile, different goal. It is the protocol we use most often for metabolically healthy men who want a thumb on the appetite scale without becoming a smaller version of themselves.
What is a GLP-1 microdose?
A GLP-1 microdose is a sub-therapeutic dose of a GLP-1 receptor agonist, typically 0.25 to 0.5 mg of semaglutide weekly, used for metabolic signaling rather than aggressive weight loss. The obesity-trial dose is 2.4 mg weekly. The microdose range sits at one-tenth to one-fifth of that.
The mechanism is the same. Same receptor, same gut-brain axis, same insulin response. The difference is amplitude. You get the metabolic effects without saturating the appetite-suppression and gastric-emptying signals.
Why anyone would skip the higher dose
The obesity trials were designed around patients with a BMI of 30 or above. The endpoint was percent of body weight lost over 68 weeks. The doses that maximized that endpoint became the labeled dose.
That dose answers a question most of our patients are not asking. A 38-year-old man at 22% body fat is not trying to lose 15% of his weight. He wants:
- Less food noise between meals.
- Smoother post-meal glucose, especially in the afternoon slump.
- A small, durable reduction in visceral fat over months.
- Insulin sensitivity that holds when life gets stressful.
The microdose hits all four targets. The 2.4 mg dose hits them too, alongside a weight trajectory he does not want and a side-effect burden he does not need.
How a microdose protocol differs from the obesity protocol
| Variable | Obesity protocol | Microdose protocol |
|---|---|---|
| Weekly dose | Titrate to 2.4 mg | Hold at 0.25 to 0.5 mg |
| Primary goal | 15% to 21% weight loss | Appetite regulation, glucose smoothing |
| Loss rate | 0.5% to 1.5% body weight per week | 0.1% to 0.3% per week, often plateau |
| Side effect profile | Nausea common, GI prominent | Largely subclinical for most men |
| Duration | 68 weeks plus maintenance | 12 to 24 weeks, then reassess |
| Muscle preservation focus | Critical | Easier by default, still important |
The microdose is not a watered-down version of the obesity dose. It is a different protocol with a different endpoint.
Who fits the microdose protocol
The men we put on a microdose typically share a profile:
- BMI between 24 and 29, not frankly obese.
- Body fat between 18% and 28%.
- Rising fasting insulin or post-meal glucose excursions on a CGM.
- Visceral fat creeping up on DEXA, even if total weight is steady.
- A job and a training routine they do not want disrupted by a week of nausea.
Men outside this profile usually need a different lever. A man at 14% body fat with normal labs does not need a GLP-1 at all. A man at 35% body fat with an A1c of 6.4 needs the obesity protocol, not the microdose.
Side effects at microdose
Most men on 0.25 mg weekly report nothing. A subset gets mild early-week nausea that resolves in two or three doses. The headline GI side effects of the higher dose, the kind that show up in trial discontinuation data, are largely absent at this range.
The side effect we still watch for is the same one we watch for at any dose: lean mass loss. A small calorie deficit is still a calorie deficit. Protein floor of 1.6 g/kg and three resistance sessions a week stay non-negotiable. We cover that in Muscle loss on GLP-1s.
How long it takes to work
Appetite shift is usually noticeable within one to two weeks, even at 0.25 mg. The change is subtle. Most men describe it as "I stop eating before the plate is empty" rather than "I am not hungry." Glucose smoothing on a CGM is measurable inside a month. Visceral fat moves on the order of three to six months.
If nothing has shifted by week six, the dose is too low for that patient and we titrate up, usually to 0.5 mg.
Where this lands
The microdose protocol is not for everyone. A man who needs to lose 60 pounds needs the dose that was studied for that. A man who wants the metabolic signal without the cliff is a different patient, and the dose should match.
If you have read about Ozempic and assumed the only protocol is the one on the ads, the broader GLP-1 picture is worth a closer look. The dose is the lever. The molecule is just the starting point.
